BioCentury
ARTICLE | Clinical News

Vesigenurtacel-L: Phase I/II amended

August 18, 2014 7:00 AM UTC

Heat Biologics amended a U.S. Phase I/II trial of vesigenurtacel-L in about 84 patients who have undergone transurethral resection of bladder tumor. Vesigenurtacel-L will now be given in combination w...